TrialAnnals of the rheumatic diseases2012

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.

Josef S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.